CoChat
Sign Up
Cited by 32

The DOI matches its Crossref record.

Immunohistochemical analysis of RHAMM expression in normal and neoplastic human tissues: a cell cycle protein with distinctive expression in mitotic cells and testicular germ cells

Chen, Yao-Tseng, Chen, Zhengming, Du, Yi-Chieh Nancy·2018·Oncotarget
DOI 10.18632/oncotarget.24939PMC PMC5940366
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.24939

Cites

Statistics

Figures

Figure 1 RHAMM expression in normal tissues Immunohistochemical staining identified scattered RHAMM-positive cells in (A) basal and parabasal cells of skin, (B) base of the crypts in small intestine, (C) bone marrow, (D) germinal centers in tonsil with a predominance in dark zones, (E) thymic cortex, and (F) placental trophoblasts. All positive cells showed cytoplasmic staining.
Figure 1 RHAMM expression in normal tissues Immunohistochemical staining identified scattered RHAMM-positive cells in (A) basal and parabasal cells of skin, (B) base of the crypts in small intestine, (C) bone marrow, (D) germinal centers in tonsil with a predominance in dark zones, (E) thymic cortex, and (F) placental trophoblasts. All positive cells showed cytoplasmic staining.CC BY · PubMed Central
Figure 2 RHAMM expression in the testis and seminoma (A) Spermatocytes in the testis showed strong cytoplasmic expression. Weak expression was seen in the spermatogonia at the periphery of the seminiferous tubules. Spermatids and spermatozoa were RHAMM-negative. (B and C) Classic seminoma had variable RHAMM positivity, from negative (B) to up to 20% RHAMM-positive cells with weak to moderate intensity (C). (D) Spermatocytic tumors showed strong RHAMM staining in approximately 30% of the tumor cells.
Figure 2 RHAMM expression in the testis and seminoma (A) Spermatocytes in the testis showed strong cytoplasmic expression. Weak expression was seen in the spermatogonia at the periphery of the seminiferous tubules. Spermatids and spermatozoa were RHAMM-negative. (B and C) Classic seminoma had variable RHAMM positivity, from negative (B) to up to 20% RHAMM-positive cells with weak to moderate intensity (C). (D) Spermatocytic tumors showed strong RHAMM staining in approximately 30% of the tumor cells.CC BY · PubMed Central
Figure 3 RHAMM expression in various tumors RHAMM expression was highly variable among different tumors. Examples of no or low expression included papillary thyroid carcinoma (A) and medullary thyroid carcinoma (B). In comparison, examples of abundant expression included a lung adenocarcinoma (C) and small cell carcinoma of the lung (D). Comparison of RHAMM in poorly-differentiated squamous cell carcinoma (of the lung) (E) and condyloma acuminatum (F) showed more abundant expression of RHAMM in the former.
Figure 3 RHAMM expression in various tumors RHAMM expression was highly variable among different tumors. Examples of no or low expression included papillary thyroid carcinoma (A) and medullary thyroid carcinoma (B). In comparison, examples of abundant expression included a lung adenocarcinoma (C) and small cell carcinoma of the lung (D). Comparison of RHAMM in poorly-differentiated squamous cell carcinoma (of the lung) (E) and condyloma acuminatum (F) showed more abundant expression of RHAMM in the former.CC BY · PubMed Central
Figure 4 RHAMM expression in mitotic cells (A) Squamous cell carcinoma showed strong RHAMM staining of all mitotic figures, in addition to some cells with weak cytoplasmic staining. (B–F) RHAMM staining in mitotic anaphase (B, C), metaphase (D, E), and in a tumor cell with abnormal tripolar mitosis (F) in a small cell lung carcinoma.
Figure 4 RHAMM expression in mitotic cells (A) Squamous cell carcinoma showed strong RHAMM staining of all mitotic figures, in addition to some cells with weak cytoplasmic staining. (B–F) RHAMM staining in mitotic anaphase (B, C), metaphase (D, E), and in a tumor cell with abnormal tripolar mitosis (F) in a small cell lung carcinoma.CC BY · PubMed Central
Figure 5 Comparison of RHAMM expression (A1–F1) with cyclin B2 expression (A2–F2) Similar expression patterns were seen in the thymus (A), tonsil (B), squamous cell carcinoma (C), and testis (D). However, spermatocytic tumor showed consistent and strong expression of RHAMM expression (E1) but not cyclin B2 (E2), while classic seminoma, generally weak for RHAMM (F1), showed strong expression of cyclin B2 (F2).
Figure 5 Comparison of RHAMM expression (A1–F1) with cyclin B2 expression (A2–F2) Similar expression patterns were seen in the thymus (A), tonsil (B), squamous cell carcinoma (C), and testis (D). However, spermatocytic tumor showed consistent and strong expression of RHAMM expression (E1) but not cyclin B2 (E2), while classic seminoma, generally weak for RHAMM (F1), showed strong expression of cyclin B2 (F2).CC BY · PubMed Central
Figure 6 Comparison of RHAMM expression (red) with phospho-Histone H3 expression (brown) by double-immunostaining (A) a spermatocytic tumor and (B) non-neoplastic testis.
Figure 6 Comparison of RHAMM expression (red) with phospho-Histone H3 expression (brown) by double-immunostaining (A) a spermatocytic tumor and (B) non-neoplastic testis.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 26

  1. Turley, 1982, Purification of a hyaluronate-binding protein fraction that modifies cell social behavior, Biochem Biophys Res Commun, 108, 1016, 10.1016/0006-291X(82)92101-5 · DOI
  2. Knudson, 2001, Cartilage proteoglycans, Semin Cell Dev Biol, 12, 69, 10.1006/scdb.2000.0243 · DOI
  3. Hart, 1999, The intracellular hyaluronan receptor RHAMM/IHABP interacts with microtubules and actin filaments, J Cell Sci, 112, 3943, 10.1242/jcs.112.22.3943 · DOI
  4. Turley, 1996, HA receptors: regulators of signalling to the cytoskeleton, J Cell Biochem, 61, 569, 10.1002/(SICI)1097-4644(19960616)61:4<569::AID-JCB10>3.0.CO;2-B · DOI
  5. Lugli, 2017, The hyaluronan-mediated motility receptor RHAMM promotes growth, invasiveness and dissemination of colorectal cancer, Oncotarget, 8, 70617, 10.18632/oncotarget.19904 · DOI
  6. Varmus, 2011, Receptor for hyaluronan-mediated motility isoform B promotes liver metastasis in a mouse model of multistep tumorigenesis and a tail vein assay for metastasis, Proc Natl Acad Sci U S A, 108, 16753, 10.1073/pnas.1114022108 · DOI
  7. Du, 2016, Expression of the receptor for hyaluronic acid mediated motility (RHAMM) is associated with poor prognosis and metastasis in non-small cell lung carcinoma, Oncotarget, 7, 39957, 10.18632/oncotarget.9554 · DOI
  8. Tzankov, 2015, Receptor for hyaluronic acid-mediated motility (RHAMM, CD168) expression is prognostically important in both nodal negative and nodal positive large cell lung cancer, J Clin Pathol, 68, 368, 10.1136/jclinpath-2014-202819 · DOI
  9. Hirata, 2015, Receptor for Hyaluronic Acid-Mediated Motility is Associated with Poor Survival in Pancreatic Ductal Adenocarcinoma, J Cancer, 6, 1093, 10.7150/jca.12990 · DOI
  10. Natsugoe, 2011, Prognostic impact of CD168 expression in gastric cancer, BMC Cancer, 11, 106, 10.1186/1471-2407-11-106 · DOI
  11. Lugli, 2015, Expression of the hyaluronan-mediated motility receptor RHAMM in tumor budding cells identifies aggressive colorectal cancers, Hum Pathol, 46, 1573, 10.1016/j.humpath.2015.07.010 · DOI
  12. Milde-Langosch, 2016, RHAMM splice variants confer radiosensitivity in human breast cancer cell lines, Oncotarget, 7, 21428, 10.18632/oncotarget.7258 · DOI
  13. Jass, 2006, Overexpression of the receptor for hyaluronic acid mediated motility is an independent adverse prognostic factor in colorectal cancer, Mod Pathol, 19, 1302, 10.1038/modpathol.3800648 · DOI
  14. Dall, 2003, Expression of the hyaluronan receptor RHAMM in endometrial carcinomas suggests a role in tumour progression and metastasis, J Cancer Res Clin Oncol, 129, 161, 10.1007/s00432-003-0415-0 · DOI
  15. Kruk, 2017, Increased RHAMM expression relates to ovarian cancer progression, J Ovarian Res, 10, 66, 10.1186/s13048-017-0360-1 · DOI
  16. Chou, 2005, Integrative genomics based identification of potential human hepatocarcinogenesis-associated cell cycle regulators: RHAMM as an example, Biochem Biophys Res Commun, 330, 489, 10.1016/j.bbrc.2005.03.005 · DOI
  17. Schmitt, 2002, Receptor for hyaluronan acid-mediated motility (RHAMM) is a new immunogenic leukemia-associated antigen in acute and chronic myeloid leukemia, Exp Hematol, 30, 1029, 10.1016/S0301-472X(02)00874-3 · DOI
  18. Engeland, 2008, RHAMM is differentially expressed in the cell cycle and downregulated by the tumor suppressor p53, Cell Cycle, 7, 3448, 10.4161/cc.7.21.7014 · DOI
  19. Lockhart, 2001, Transcriptional regulation and function during the human cell cycle, Nat Genet, 27, 48, 10.1038/83751 · DOI · Paper page
  20. Botstein, 2002, Identification of genes periodically expressed in the human cell cycle and their expression in tumors, Mol Biol Cell, 13, 1977, 10.1091/mbc.02-02-0030 · DOI · Paper page
  21. Nussenzweig, 2012, Identification of human germinal center light and dark zone cells and their relationship to human B-cell lymphomas, Blood, 120, 2240, 10.1182/blood-2012-03-415380 · DOI
  22. Hua, 2010, Regulation of cyclin B2 expression and cell cycle G2/m transition by menin, J Biol Chem, 285, 18291, 10.1074/jbc.M110.106575 · DOI
  23. Old, 2011, Chromosome X-encoded cancer/testis antigens show distinctive expression patterns in developing gonads and in testicular seminoma, Hum Reprod, 26, 3232, 10.1093/humrep/der330 · DOI
  24. Lange, 2016, Impaired Planar Germ Cell Division in the Testis, Caused by Dissociation of RHAMM from the Spindle, Results in Hypofertility and Seminoma, Cancer Res, 76, 6382, 10.1158/0008-5472.CAN-16-0179 · DOI
  25. Frappart, 2017, HMMR acts in the PLK1-dependent spindle positioning pathway and supports neural development, Elife, 6, e28672, 10.7554/eLife.28672 · DOI
  26. Ringhoffer, 2009, RHAMM (CD168) is overexpressed at the protein level and may constitute an immunogenic antigen in advanced prostate cancer disease, Neoplasia, 11, 956, 10.1593/neo.09694 · DOI

Cited by

Sorted by citations

Metadata

Authors
Chen, Y.-T., Chen, Z., & Du, Y.-C. N.
Affiliations
  • Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, 10065 NY, USA
  • Division of Biostatistics and Epidemiology, Department of Healthcare Policy and Research, Weill Cornell Medicine, New York, 10065 NY, USA
Venue
Oncotarget
Publisher
Impact Journals, LLC
Published
2018-04-20
Volume
9
Issue
30
Pages
20941-20952
ISSN
1949-2553
DOI
10.18632/oncotarget.24939
PMC
PMC5940366
Cited by
32
References
0
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review